WO2010012972A3 - Novel bacterial cells and uses thereof - Google Patents

Novel bacterial cells and uses thereof Download PDF

Info

Publication number
WO2010012972A3
WO2010012972A3 PCT/GB2009/001433 GB2009001433W WO2010012972A3 WO 2010012972 A3 WO2010012972 A3 WO 2010012972A3 GB 2009001433 W GB2009001433 W GB 2009001433W WO 2010012972 A3 WO2010012972 A3 WO 2010012972A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
cell
orf18
homologue
fragment
Prior art date
Application number
PCT/GB2009/001433
Other languages
French (fr)
Other versions
WO2010012972A2 (en
Inventor
Michael Gasson
Claire Shearman
Regis Stentz
Original Assignee
Plant Bioscience Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plant Bioscience Limited filed Critical Plant Bioscience Limited
Publication of WO2010012972A2 publication Critical patent/WO2010012972A2/en
Publication of WO2010012972A3 publication Critical patent/WO2010012972A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
    • A23C19/061—Addition of, or treatment with, microorganisms
    • A23C19/062—Addition of, or treatment with, microorganisms using only lactic acid bacteria, e.g. pediococcus, leconostoc or bifidus sp., or propionic acid bacteria; Treatment with non-specified acidifying bacterial cultures
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/20—Synthetic spices, flavouring agents or condiments
    • A23L27/24—Synthetic spices, flavouring agents or condiments prepared by fermentation
    • A23L27/25—Dairy flavours
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8103—Exopeptidase (E.C. 3.4.11-19) inhibitors
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

The present invention provides a bacterial host cell having improved cell permeability properties, the cell comprising an Orf18 gene or species homologue thereof, or a fragment or variant of the same encoding a polypeptide having the activity of the Orf18 gene product or species homologue thereof, wherein the gene, homologue, fragment or variant is under the control of an heterologous promoter (inducible or constitutively active) which permits sufficient expression of the gene, homologue, fragment or variant to increase the permeability of the cell wall. "Orf18 and the "orf18 gene" are also known as "CsiA" and the "csiA gene" respectively. In one embodiment, the host cell is a Lactococcus lactis cell in which a chromosomally-integrated Orf18 gene naturally present in the cell is inactivated. The invention further provides the use of such host cells in the production of polypeptides. In addition, the invention provides pharmaceutical compositions of the host cells and the use thereof for administering a bioactive agent to the human or animal body (for example, to the Gl tract).
PCT/GB2009/001433 2008-06-05 2009-06-05 Novel bacterial cells and uses thereof WO2010012972A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12910908P 2008-06-05 2008-06-05
US61/129,109 2008-06-05

Publications (2)

Publication Number Publication Date
WO2010012972A2 WO2010012972A2 (en) 2010-02-04
WO2010012972A3 true WO2010012972A3 (en) 2010-04-01

Family

ID=41467002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/001433 WO2010012972A2 (en) 2008-06-05 2009-06-05 Novel bacterial cells and uses thereof

Country Status (1)

Country Link
WO (1) WO2010012972A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386641A1 (en) 2010-05-11 2011-11-16 Université Catholique De Louvain Method for extracellular production of recombinant biomolecules in a microorganism
CN102174487B (en) * 2010-12-20 2012-11-07 江苏省农业科学院 Listeria phage endolysin and preparation method as well as application thereof
CN108424464A (en) * 2011-10-05 2018-08-21 洛克菲勒大学 Dimerization bacteriophage lysin
CN106148455B (en) * 2015-03-25 2020-10-02 普莱柯生物工程股份有限公司 Inducer and application thereof
EP3692149B1 (en) * 2017-10-06 2023-01-04 Micreos Human Health B.V. Treatment of a condition associated with infection with an oncogenic bacterium
CN107670023B (en) * 2017-10-10 2021-10-22 中国科学院武汉病毒研究所 New application of V12CBD protein and coding gene thereof
CN114214436A (en) * 2021-11-17 2022-03-22 中国水产科学研究院南海水产研究所 Method for evaluating bacterial conjugation transfer efficiency based on quantitative PCR technology

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt [online] 6 March 2007 (2007-03-06), "SubName: Full=Putative uncharacterized protein;", XP002564517, retrieved from EBI accession no. UNIPROT:A2RL11 Database accession no. A2RL11 *
MILLS SUSAN ET AL: "Insertional inactivation of determinants for Mg2+ and Co2+ transport as a tool for screening recombinant Lactococcus species clones.", August 2005, APPLIED AND ENVIRONMENTAL MICROBIOLOGY AUG 2005, VOL. 71, NR. 8, PAGE(S) 4897 - 4901, ISSN: 0099-2240, XP002564534 *
RUYTER DE P G G A ET AL: "FOOD-GRADE CONTROLLED LYSIS OF LACTOCOCCUS LACTIS FOR ACCELERATED CHEESE RIPENING", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 15, no. 10, 1 October 1997 (1997-10-01), pages 976 - 979, XP008042228, ISSN: 1087-0156 *
STENTZ REGIS ET AL: "CsiA is a bacterial cell wall synthesis inhibitor contributing to DNA translocation through the cell envelope", MOLECULAR MICROBIOLOGY, vol. 72, no. 3, May 2009 (2009-05-01), pages 779 - 794, XP002564516 *
WEGMANN U ET AL: "Complete genome sequence of the prototype lactic acid bacterium Lactococcus lactis subsp cremoris MG1363", 1 April 2007, JOURNAL OF BACTERIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, PAGE(S) 3256 - 3270, ISSN: 0021-9193, XP002465567 *

Also Published As

Publication number Publication date
WO2010012972A2 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
WO2010012972A3 (en) Novel bacterial cells and uses thereof
Gervasi et al. Expression and delivery of an endolysin to combat Clostridium perfringens
Zhang et al. High expression of a plectasin-derived peptide NZ2114 in Pichia pastoris and its pharmacodynamics, postantibiotic and synergy against Staphylococcus aureus
CN102199196B (en) Gene engineering antibacterial peptide and preparation method and application thereof
MX362028B (en) Extended recombinant polypeptides and compositions comprising same.
US8383102B2 (en) Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens
CN107735098A (en) Antimicrobial therapy
AU2010288559A8 (en) New endolysin OBPgpLYS
BRPI1010880A2 (en) growth hormone polypeptides and methods of making and using them.
CN106659748B (en) Acinetobacter lysin
EP3933029A3 (en) Reduced colonization of microbes at the mucosa
WO2008084115A3 (en) Lactococcus promoters and uses thereof
JP2018502600A5 (en)
MX339277B (en) Immunity inducer.
GB201018518D0 (en) Novel endolysin
IN2012DN02981A (en)
Kojic et al. Cloning and expression of a novel lactococcal aggregation factor from Lactococcus lactis subsp. lactis BGKP1
NZ593893A (en) Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases
NZ597306A (en) Mesenchymal stem cell differentiation
MX2019011808A (en) Engineered gram-negative endolysins.
WO2008134068A3 (en) Synthetic expression vectors for insect cells
Lin et al. Characterization and bioactivity of hepcidin-2 in zebrafish: Dependence of antibacterial activity upon disulfide bridges
WO2009001260A3 (en) Cosmetic use of apolipoprotein d type proteins
WO2009046464A8 (en) Articular cartilage gene therapy with recombinant vector encoding bmp-7
Lahiri et al. Bacteriocin: A natural approach for food safety and food security

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09784598

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09784598

Country of ref document: EP

Kind code of ref document: A2